血清碱性磷酸酶水平与动脉瘤性蛛网膜下腔出血后血管造影血管痉挛、迟发性脑缺血所致临床恶化及功能结局相关
该前瞻性队列研究纳入2014年1月至2018年5月连续196例动脉瘤性蛛网膜下腔出血患者,并与78名健康对照比较,随访6个月。入院血清碱性磷酸酶患者高于对照(71 vs. 61 U/L,p=0.0002),重度影像学状态(改良Fisher 3-4)者高于轻度者(77 vs. 61.5 U/L,p=0.0005)。多变量分析显示较高碱性磷酸酶与血管造影血管痉挛(OR 1.019,95%CI 1.002-1.036,p=0.026)、迟发性脑缺血所致临床恶化(OR 1.019,95%CI 1.001-1.037,p=0.037)及不良结局(OR 1.083,95%CI 1.041-1.127,p<0.001)独立相关。作者认为需进一步研究以检验血清碱性磷酸酶作为结局预测指标的可能作用。
要点
- 入院血清碱性磷酸酶在动脉瘤性蛛网膜下腔出血患者高于健康对照(71 vs. 61 U/L,p=0.0002)。
- 改良Fisher 3-4级患者碱性磷酸酶高于1-2级者(77 vs. 61.5 U/L,p=0.0005),且与改良Fisher评分相关(r=0.246,p=0.001)。
- 多变量分析中较高碱性磷酸酶与血管造影血管痉挛独立相关(OR 1.019,95%CI 1.002-1.036,p=0.026)。
- 较高碱性磷酸酶与迟发性脑缺血所致临床恶化独立相关(OR 1.019,95%CI 1.001-1.037,p=0.037)。
- 较高碱性磷酸酶与6个月不良结局独立相关(OR 1.083,95%CI 1.041-1.127,p<0.001),作者认为需进一步研究其作为结局预测指标的作用。
适用人群与场景
- 2014年1月至2018年5月连续纳入的动脉瘤性蛛网膜下腔出血患者196例,随访6个月。
- 对照为78名健康个体。
研究设计与关键结果
- 前瞻性队列研究,纳入196例动脉瘤性蛛网膜下腔出血患者和78名健康对照,随访6个月。
- 入院血清碱性磷酸酶患者高于对照(71 vs. 61 U/L,p=0.0002),但重度临床状态(WFNS 4-5)与轻度者无显著差异(72 vs. 63 U/L,p=0.3362)。
- 重度影像学状态(改良Fisher 3-4)者碱性磷酸酶高于轻度者(77 vs. 61.5 U/L,p=0.0005),改良Fisher评分与碱性磷酸酶相关(r=0.246,p=0.001)。
- 多变量分析:较高碱性磷酸酶与血管造影血管痉挛(OR 1.019,95%CI 1.002-1.036,p=0.026)和迟发性脑缺血所致临床恶化(OR 1.019,95%CI 1.001-1.037,p=0.037)独立相关。
- 较高WFNS评分、改良Fisher评分和碱性磷酸酶水平与不良结局独立相关(血清碱性磷酸酶 OR 1.083,95%CI 1.041-1.127,p<0.001)。
- 基于103例患者的趋势分析:入院日 vs. 入院后7-9天中位数72 vs. 60 U/L(p=0.0012),入院后3-5天 vs. 7-9天70 vs. 60 U/L(p=0.0052),入院后12-14天中位数升至84 U/L(p<0.0001)。
- 不良结局患者碱性磷酸酶在入院日(86 vs. 67 U/L,p=0.0122)、入院后3-5天(80 vs. 64 U/L,p=0.0044)、7-9天(75 vs. 53.5 U/L,p<0.0001)高于良好结局者,入院后12-14天无显著差异。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需进一步研究以检验血清碱性磷酸酶作为动脉瘤性蛛网膜下腔出血患者结局预测指标的可能作用。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Alkaline phosphatase (ALP) has been implicated to be associated with poor outcome in ischemic stroke patients, yet its role in aneurysmal subarachnoid hemorrhage (aSAH) patients is unknown. The current study aimed to investigate the on-admission and short-term variation trend of ALP levels in aSAH patients as well as its associations with vasospasm, delayed cerebral ischemia (DCI), and outcome after aSAH.
METHODS: Between January 2014 and May 2018, all consecutive aSAH patients were prospectively enrolled. Blood samples from patients and 78 healthy individuals were obtained. Baseline information, clinical data, and radiologic data were collected, and serum ALP levels during hospitalization were measured. Patients were followed up for 6 months.
RESULTS: One hundred and ninety-six aSAH patients were included. The serum ALP levels in aSAH patients were significantly higher compared to controls (71 vs. 61 U/L, p = 0.0002), yet did not differ significantly between patients with severe (WFNS 4-5) and mild clinical condition (72 vs. 63 U/L, p = 0.3362). However, ALP was significantly higher in patients with severe radiologic status (modified Fisher 3-4) compared to those with mild radiologic status (77 vs. 61.5 U/L, p = 0.0005). A significant correlation emerged between modified Fisher score and ALP level (r = 0.246, p = 0.001). Multivariable analysis found that higher ALP level was associated with angiographic vasospasm (OR 1.019, 95% CI 1.002-1.036, p = 0.026) and DCI-caused clinical deterioration (OR 1.019, 95% CI 1.001-1.037, p = 0.037), while higher WFNS score, modified Fisher score, and ALP level were independently associated with unfavorable outcome (serum ALP level, OR 1.083, 95% CI 1.041-1.127, p < 0.001). Trend analysis of ALP level based on 103 patients' data revealed a significant decrease in ALP level on post-admission day 7-9 (median; on-admission day vs. post-admission day 7-9, 72 vs. 60 U/L, p = 0.0012; post-admission day 3-5 vs. day 7-9, 70 vs. 60 U/L, p = 0.0052) and subsequent increase in ALP level on post-admission day 12-14 (median, 84 U/L, p < 0.0001). Higher ALP levels were observed in patients with unfavorable outcome on on-admission day, post-admission day 3-5, and 12-14 (median; unfavorable vs. favorable; on-admission day, 86 vs. 67 U/L, p = 0.0122; post-admission day 3-5, 80 vs. 64 U/L, p = 0.0044; post-admission day 7-9, 75 vs. 53.5 U/L, p < 0.0001) but not on post-admission day 12-14.
CONCLUSIONS: Elevated serum ALP level is associated with vasospasm, DCI-caused clinical deterioration, and functional outcome after aSAH. Further studies are required to examine the potential role of serum ALP as an outcome predictor for aSAH patients.
参考来源
- Zhu Y, Jiang H, Li Y, et al. Serum Alkaline Phosphatase Level is Associated with Angiographic Vasospasm, Delayed Cerebral Ischemia-Caused Clinical Deterioration, and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2019. PMID: 31016639. doi:10.1007/s12028-019-00714-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。